ZTS

Business profile & competitive position

Zoetis Inc. (ZTS) is classified under Healthcare / Drug Manufacturers – Specialty & Generic, but its actual business is animal health. The company discovers, develops, manufactures and commercializes medicines, vaccines, diagnostics, biodevices, genetic tests and precision-health services for animals. Its products are sold in more than 100 countries across eight core species: dogs, cats and horses in the companion-animal segment, plus cattle, swine, poultry, fish and sheep in the livestock segment.

In 2025, companion animal products generated roughly 70% of revenue, while livestock products accounted for roughly 29%. Geographically, U.S. revenue was $5,097 million, or 54% of total revenue, and International revenue was $4,254 million, or 45%. The company also shows meaningful product concentration: the top two product lines, Simparica/Simparica Trio and Apoquel/Apoquel Chewable, contributed approximately 16% and 12% of revenue respectively in 2025, while the top five product lines together contributed approximately 42%.

Those revenue shares matter when reading the margin data. Zoetis carries a 27.5% net margin and a 69.3% ROE. Numbers like that, in a specialty animal-health business, generally point to a portfolio with pricing power and repeat-purchase characteristics—especially in companion-animal parasiticides and dermatology. The flip side of the same data is that a small number of products and markets carry outsized weight, meaning performance of key brands can move the overall narrative quickly.

Financial posture

As of the current snapshot, Zoetis had a market capitalization of $32.3 billion, a trailing P/E of 12.7, a net margin of 27.5%, ROE of 69.3% and a beta of 0.73. The share price was $77.02, with the 50-day EMA at $77.79 and RSI at 52.3.

The combination of a sub-1.0 beta and mid-teens P/E puts Zoetis in a relatively defensive valuation corner for a healthcare name. A 27.5% net margin is well above what most diversified human-pharma or animal-health peers produce, and a 69.3% ROE signals either very high capital efficiency or a leveraged capital structure—or both. For a research analyst, the key follow-up is how durable those returns are once key products move through their lifecycle. A 12.7 P/E does not necessarily mean the stock is cheap or expensive on its own; it means the market is pricing in either modest growth or some risk to the current margin/return profile. Low beta supports the idea that the stock has historically been less volatile than the broader market, but it does not guarantee future stability.

Strategic priorities & outlook

Zoetis’s most recent 10-K outlines several operational priorities. The first is continued investment in discovery and development of new chemical, biopharmaceutical and biological entities, alongside product lifecycle innovation. A second priority is vaccine development, specifically for emerging infectious diseases, using what management describes as a “first to know and fast to market” operating philosophy.

On the diagnostics side, Zoetis is integrating new AI-driven capabilities into its Vetscan Imagyst platform to expand point-of-care testing in veterinary clinics. Operationally, the company plans to eliminate the one-month reporting lag for subsidiaries outside the U.S. in 2026 and align the fiscal years of its U.S. and International segments. That accounting change should make quarterly results easier to compare but does not alter the underlying cash economics of the business.

One milestone already behind the company is the October 31, 2024 divestiture of its medicated feed additive product portfolio, certain water-soluble products and related assets. Removing that portfolio likely reshaped the livestock revenue mix and may have improved margin clarity, but it also means the company is relying even more heavily on the remaining companion-animal and livestock brands.

Macro & geopolitical exposure

As a global animal-health drug and vaccine manufacturer, Zoetis sits at the intersection of three broad macro themes: regulatory oversight, international trade and currency exposure, and livestock commodity cycles.

Regulators around the world treat animal medicines, vaccines and diagnostic products as controlled products, so approvals, label changes and manufacturing inspections can materially affect launch timelines. Intellectual-property rules also matter for specialty and generic drug exposure—new products enjoy periods of exclusivity, while older products eventually face generic or biosimilar competition. Supply chains for biologics and vaccines are sensitive to cold-chain logistics, ingredient sourcing and manufacturing capacity, which can be disrupted by trade policy, pandemic-related restrictions or geopolitical friction.

International revenue at 45% of the total means foreign-exchange translation is a real variable in Zoetis’s reported earnings. Tariffs or trade disputes affecting the movement of finished goods or active ingredients could influence costs and pricing. On the demand side, livestock revenue is tied to farm economics: higher feed costs, lower livestock prices or herd reductions can reduce spending on animal health. Companion-animal revenue tends to be steadier because pet owners view vaccines and chronic-care products as non-discretionary, but it is still exposed to consumer confidence and veterinary visit trends.

Recent developments

The most recent headlines on Zoetis carry dates that line up around its early-August 2026 earnings report.

• On August 30, 2026, Seeking Alpha published “Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead.” The title suggests a view that the merged or integrated company is positioned for improved free-cash-flow generation.
• On August 29, 2026, Defense World reported that Blackhill Capital Inc. cut its stock position in Zoetis. Institutional position reductions are not directional verdicts on the whole company, but they show that at least one holder reduced exposure near the upper-$70 price area.
• On August 19, 2026, Motley Fool highlighted Zoetis among “3 High-Yielding Dividend Stocks That Have Doubled Their Payouts in 5 Years.” That framing emphasizes Zoetis’s capital-return track record.
• On August 18, 2026, Seeking Alpha ran “Zoetis: A Solid Long-Term Buy After Harsh Drawdown.” The headline speaks for itself, but it is still just one opinion from that date.

None of these headlines are investment recommendations; they are simply the narrative around the stock during a period when the price had already come down from prior highs.

Earnings behavior & post-earnings drift

Zoetis has a strong headline beat record over the past eight quarters: it beat earnings estimates in 7 out of 8 quarters, an 88% beat rate, with an average surprise of 3.9%. Yet the average 5-day price move after those reports is -4.1%, classified as a negative post-earnings drift. That is where the story becomes interesting for traders: beating the number has not reliably translated into a rally over the following week.

Looking at the last four quarters, the disconnect is clear:

• August 6, 2026: EPS came in at $1.87 versus an estimate of $1.85, a 1.1% beat. The stock fell 5.97% the next day and was down 1.85% over the following five days.
• May 7, 2026: EPS of $1.53 missed the $1.60 estimate by 4.4%. The stock dropped 5.13% the next day and 13.55% over five days.
• February 12, 2026: EPS of $1.48 beat the $1.40 estimate by 5.7%. The stock rose 0.8% the next day and 2.5% over five days—the only beat in this window that produced a positive drift.
• November 4, 2025: EPS of $1.70 beat the $1.62 estimate by 4.9%. The stock still fell 3.19% the next day and 3.49% over five days.

The pattern suggests that headline beats are not enough. Forward guidance, segment momentum, foreign-exchange commentary and margin trajectory appear to determine how the market prices the report. The May miss is a useful baseline: when Zoetis misses, the punishment can be severe. For the next scheduled report on November 3, 2026 before the market open, the consensus EPS estimate is $1.51. Whether it beats or misses that figure, the price reaction over the following days is what traders should track most closely.

For a deeper dive into how institutional analysts currently view Zoetis—forward estimates, rating distributions, price targets and peer comparisons—explore the full institutional verdict on the ticker page.